文献速递临床试验与 GCP流行病学与生物统计

腋窝淋巴结清扫与不清扫对浸润性乳腺癌伴前哨淋巴结转移女性10年总生存的影响:ACOSOG Z0011(Alliance)随机临床试验

Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
PubMed 文献 · JAMA · 2017-01-01

该3期随机临床试验自1999年5月至2004年12月纳入115个中心的891例临床T1或T2浸润性乳腺癌、无腋窝可触及淋巴结、1或2枚前哨淋巴结转移的女性,比较单纯前哨淋巴结清扫(SLND)与腋窝淋巴结清扫(ALND)的10年总生存。中位随访9.3年,10年总生存SLND组86.3% vs ALND组83.6%(HR 0.85,单侧95%CI 0-1.16,非劣效P=0.02),SLND非劣效于ALND。

要点

  • 10年总生存SLND组86.3% vs ALND组83.6%,HR 0.85(单侧95%CI 0-1.16),非劣效P=0.02。
  • 10年无病生存SLND组80.2% vs ALND组78.2%,HR 0.85(95%CI 0.62-1.17),P=0.32。
  • 第5至10年间,SLND组出现1例区域复发,ALND组无区域复发;10年区域复发两组无显著差异。

核心结论

  • 在临床T1或T2浸润性乳腺癌、无腋窝可触及淋巴结、1或2枚前哨淋巴结转移的女性中,单纯前哨淋巴结清扫的10年总生存非劣效于腋窝淋巴结清扫。
  • 基于10年结果,这些发现不支持在该患者人群中常规使用腋窝淋巴结清扫。

研究设计与样本

  • ACOSOG Z0011(Alliance)3期随机临床试验,1999年5月至2004年12月从115个中心(学术与社区医学中心)入组患者。
  • 纳入标准为临床T1或T2浸润性乳腺癌、无腋窝可触及淋巴结、1或2枚前哨淋巴结含转移的女性。
  • 所有患者计划行肿物切除术、全乳切线放疗和辅助全身治疗,禁止第三野放疗。
  • 共891例女性随机分组(中位年龄55岁),856例(96%)完成试验(单纯前哨淋巴结清扫组446例,腋窝淋巴结清扫组445例)。
  • 末次随访日期为2015年9月29日,中位随访9.3年(四分位距6.93-10.34年)。

主要发现

  • 10年总生存:单纯前哨淋巴结清扫组86.3% vs 腋窝淋巴结清扫组83.6%(HR 0.85,单侧95%CI 0-1.16,非劣效P=0.02)。
  • 10年无病生存:单纯前哨淋巴结清扫组80.2% vs 腋窝淋巴结清扫组78.2%(HR 0.85,95%CI 0.62-1.17,P=0.32)。
  • 第5至第10年间,单纯前哨淋巴结清扫组出现1例区域复发,腋窝淋巴结清扫组无区域复发;10年区域复发两组无显著差异。

关键数值与推荐

  • 主要终点为总生存,非劣效风险比(HR)界值为1.3。
  • 次要终点为无病生存。

临床怎么用

  • 原文结论指出,这些发现不支持在该患者人群中基于10年结果常规使用腋窝淋巴结清扫。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The results of the American College of Surgeons Oncology Group Z0011 (ACOSOG Z0011) trial were first reported in 2005 with a median follow-up of 6.3 years. Longer follow-up was necessary because the majority of the patients had estrogen receptor-positive tumors that may recur later in the disease course (the ACOSOG is now part of the Alliance for Clinical Trials in Oncology). OBJECTIVE: To determine whether the 10-year overall survival of patients with sentinel lymph node metastases treated with breast-conserving therapy and sentinel lymph node dissection (SLND) alone without axillary lymph node dissection (ALND) is noninferior to that of women treated with axillary dissection. DESIGN, SETTING, AND PARTICIPANTS: The ACOSOG Z0011 phase 3 randomized clinical trial enrolled patients from May 1999 to December 2004 at 115 sites (both academic and community medical centers). The last date of follow-up was September 29, 2015, in the ACOSOG Z0011 (Alliance) trial. Eligible patients were women with clinical T1 or T2 invasive breast cancer, no palpable axillary adenopathy, and 1 or 2 sentinel lymph nodes containing metastases. INTERVENTIONS: All patients had planned lumpectomy, planned tangential whole-breast irradiation, and adjuvant systemic therapy. Third-field radiation was prohibited. MAIN OUTCOMES AND MEASURES: The primary outcome was overall survival with a noninferiority hazard ratio (HR) margin of 1.3. The secondary outcome was disease-free survival. RESULTS: Among 891 women who were randomized (median age, 55 years), 856 (96%) completed the trial (446 in the SLND alone group and 445 in the ALND group). At a median follow-up of 9.3 years (interquartile range, 6.93-10.34 years), the 10-year overall survival was 86.3% in the SLND alone group and 83.6% in the ALND group (HR, 0.85 [1-sided 95% CI, 0-1.16]; noninferiority P = .02). The 10-year disease-free survival was 80.2% in the SLND alone group and 78.2% in the ALND group (HR, 0.85 [95% CI, 0.62-1.17]; P = .32). Between year 5 and year 10, 1 regional recurrence was seen in the SLND alone group vs none in the ALND group. Ten-year regional recurrence did not differ significantly between the 2 groups. CONCLUSIONS AND RELEVANCE: Among women with T1 or T2 invasive primary breast cancer, no palpable axillary adenopathy, and 1 or 2 sentinel lymph nodes containing metastases, 10-year overall survival for patients treated with sentinel lymph node dissection alone was noninferior to overall survival for those treated with axillary lymph node dissection. These findings do not support routine use of axillary lymph node dissection in this patient population based on 10-year outcomes. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00003855.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Giuliano AE, Ballman KV, McCall L, et al. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017. PMID: 28898379. doi:10.1001/jama.2017.11470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。